Compare Apartment Investment and Management Co (AIV) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apartment Investment and Management Co vs Crispr Therapeutics AG — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $376.16M), while Crispr Therapeutics AG trades at $54.01 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 13.9× Apartment Investment and Management Co's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | CRSP | |
|---|---|---|
Market Cap | $376.16M | $5.23B |
Sector | Real Estate | Health |
52-Week High | $7.93 | $76.78 |
52-Week Low | $2.59 | $44.34 |
Enterprise Value | $738.32M | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.605, down 0.57% on the day, with a bearish technical outlook showing 13 sell signals on moving averages. The stock presents a mixed fundamental picture with a strong 400% net income margin and 228% ROE for 2025, though revenue declined to $138M from $209M in 2024. Recent earnings show volatility with two beats and two misses in the last four quarters. The company announced a $1.30 dividend for H1-2026, payable in June 2026.
AIV offers value with a P/B ratio of 0.76 and positive cash flow generation, but faces challenges from declining revenue and inconsistent earnings performance. The bearish technical setup and mixed analyst sentiment (33% buy, 67% hold) suggest cautious optimism. Key risks include execution volatility and real estate sector headwinds, while the dividend provides income support.
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
